XENAZINE

This brand name is authorized in United States. It is also authorized in Estonia, France, Israel, Lithuania, Netherlands, UK.

Active ingredients

The drug XENAZINE contains one active pharmaceutical ingredient (API):

1	Tetrabenazine UNII Z9O08YRN8O - TETRABENAZINE
	Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours.
	Read more about Tetrabenazine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XENAZINE Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N07XX06	Tetrabenazine	N Nervous system → N07 Other nervous system drugs → N07X Other nervous system drugs → N07XX Other nervous system drugs
Discover more medicines within N07XX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1595998
FR	Base de données publique des médicaments	62463044
GB	Medicines & Healthcare Products Regulatory Agency	23232
IL	מִשְׂרַד הַבְּרִיאוּת	4873
LT	Valstybinė vaistų kontrolės tarnyba	1067976
NL	Z-Index G-Standaard, PRK	50725
US	FDA, National Drug Code	67386-421, 67386-422